CytomX Therapeutics Inc (CTMX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $5.48
• Market Cap: $979.34M
• P/E Ratio: 19.27
• EPS: $0.30
• 52-Week High: $6.35
• 52-Week Low: $0.40

Market Sentiment

CytomX Therapeutics Inc currently has a Bullish sentiment score of 0.52.

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc., based in South San Francisco, California, is a pioneering biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary Probody™ technology platform. This innovative approach aims to create highly selective therapeutics that reduce off-tumor effects while enhancing targeted anti-tumor activity, addressing critical unmet needs in oncology. With a promising pipeline of product candidates at various clinical stages, CytomX is well-positi...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for CytomX Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CTMX pay dividends?

CytomX Therapeutics Inc (CTMX) does not currently pay a regular dividend.

What is CTMX's P/E ratio?

CytomX Therapeutics Inc has a price-to-earnings (P/E) ratio of 19.27.

What is CTMX's market cap?

CytomX Therapeutics Inc (CTMX) has a market capitalization of $979.34M with a current stock price of $5.48.